On June 19th, Ma Peihua, Deputy Minister of the United Front Work Department of the Minhang District Committee of Shanghai and Secretary of the Party Group of the District Federation of Industry and Commerce, led a delegation to visitIntelligent Medicine Original, where they learned in detail about Intelligent Medicine Original's business operations and the development of AI protein drug design. Qu Huiming, Head of the Commercial Construction Section of the Minhang District Federation of Industry and Commerce, accompanied the delegation. Yu Zhangsheng, Chief Scientist of Intelligent Medicine Original, and Chen Haifeng, among others, personally received the research team.

During the research visit, Secretary Ma Peihua gained an in-depth understanding of the core technologies, product portfolio, and business model of AI protein drug design at Intelligent Medicine Original. She particularly emphasized that Intelligent Medicine Original, as a company integrating artificial intelligence and healthcare, aligns with the national strategy for the development of AI in healthcare, and expressed high praise for the company's achievements.

Secretary Ma Peihua also inquired about some of the challenges the company is currently facing and expressed the Minhang District Federation of Industry and Commerce's support and concern for private enterprises. She emphasized that the Minhang District Federation of Industry and Commerce will further increase its support for private enterprises and actively support high-quality companies like Intelligent Medicine Original.

In the future, Intelligent Medicine Originalwill expand its market cooperation both domestically and internationally, enhance its technological capabilities, and contribute more to the development of AI protein drugs.

Intelligent Medicine Original is a medical technology company founded by researchers from Shanghai Jiao Tong University. Established in September 2023, the company has built a full-process, graphical, one-click generation platform for protein drug design and screening. It has also established project collaborations with several domestic and international listed pharmaceutical companies to accelerate protein drug development and build its own protein drug pipeline.

The mission of Intelligent Medicine Original is to leverage generative artificial intelligence to develop innovative drug screening algorithms, aiming to solve the problems of long screening times and low accuracy in protein drug screening. Our goal is to develop efficient and accurate protein drug screening software, focusing on peptide drug screening and conducting laboratory validation of protein activity, affinity, and solubility, with the aim of solving major challenges in endocrine, digestive, and bone diseases. We firmly believe that through the power of artificial intelligence, we can open a new chapter in drug development, bringing greater hope and possibilities to the health of all humankind.